Data from a Phase 2 clincial trial for solithromycin, a next-generation oral and intravenous fluoroketolide for the treatment of moderate to moderately-severe community acquired bacterial pneumonia (CABP) and urethritis, ... Read more
Cempra, Inc., announced that it has completed its rolling submission of a New Drug Application for solithromycin, a potential treatment for community-acquired bacterial pneumonia (CABP), to the U.S. Food and Drug Administration. The ... Read more
The Biomedical Advanced Research and Development Authority (BARDA) of the U.S. Department of Health and Human Services has announced that it will provide a $16 million dollar grant to clinical-stage pharmaceutical ... Read more
